查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2016080

葡萄膜炎治療市場報告：按治療類型、疾病類型、病因、分銷管道和地區分類，2026-2034 年

Uveitis Treatment Market Report by Treatment Type, Disease Type, Cause, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 140 Pages | 商品交期: 2-3個工作天內

價格

2025年全球葡萄膜炎治療市場規模達19億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到28億美元，2026年至2034年的複合年成長率（CAGR）為4.31%。這一顯著成長的促進因素包括：葡萄膜炎盛行率的上升、各種生物製藥和免疫抑制療法的持續研發以豐富治療方法、人們對早期診斷重要性的認知不斷提高、政府支持政策以及醫療報銷機制。

葡萄膜炎治療市場趨勢：

自體免疫疾病盛行率增加

全球自體免疫疾病盛行率的不斷上升刺激了對葡萄膜炎治療的需求。根據美國國立衛生研究院 (NIH) 估計，約有 2,350 萬美國人患有自體免疫疾病，包括類風濕性關節炎、發炎性腸道疾病、狼瘡以及其他可能導致葡萄膜炎併發症的疾病。值得注意的是，如此高的盛行率凸顯了針對自體免疫疾病的有效葡萄膜炎治療方法的巨大需求，從而刺激了市場需求。因此，隨著這些疾病在全球範圍內的增加，葡萄膜炎治療的目標不僅在於控制症狀，更在於透過靶向導致疾病的自體免疫過程來改善患者的生活品質。

生物製藥和免疫療法的進展

生物製藥和免疫調節療法透過調節免疫介導過程，徹底改變了葡萄膜炎的治療。美國國立衛生研究院 (NIH) 已核准多種生物製藥用於治療包括葡萄膜炎在內的自體免疫疾病，這表明治療方向正轉向使用經濟有效的生物製藥。與皮質類固醇等其他治療方法相比，這些治療方法具有許多優勢，例如副作用發生率較低，可影響身體其他器官，使患者更能堅持治療方案。因此，生物技術和免疫學領域的市場持續擴張，推動了生物製劑和免疫調節產品的研發，並為全球葡萄膜炎的治療市場拓展了機會。

醫療保健領域的醫療支出和研究經費增加

政府對醫療保健系統、發展策略和醫療技術進步的投入增加，正在推動葡萄膜炎治療市場價值的成長。在美國，國立衛生研究院 (NIH) 為葡萄膜炎和其他自體免疫疾病的研究提供大量資金，這得益於大學、製藥公司和醫院之間的多學科合作。這種資金支持透過加速新藥、生物製藥和治療方法的研發，進一步積極影響了葡萄膜炎新治療方法的進展。此外，政府資助的研究津貼和臨床試驗為探索新的治療方案和檢驗治療方法提供了必要的框架和資源。這些趨勢使得葡萄膜炎治療市場成為一個高度研究密集型市場，其重點在於將研究成果轉化為臨床實用產品和服務，滿足全球現有需求，並改善患者體驗。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球葡萄膜炎治療市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依治療類型分類

  • 皮質類固醇
  • 免疫抑制劑
  • 單株抗體
  • 散瞳劑
  • 抗生素
  • 抗病毒藥物
  • 抗真菌藥物
  • 止痛藥

第7章 市場區隔：依疾病類型分類

  • 前葡萄膜炎
  • 後葡萄膜炎
  • 中間葡萄膜炎
  • 全葡萄膜炎

第8章 市場崩盤：按原因分類

  • 傳染性
  • 非傳染性的

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 其他

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 主要企業
  • 主要企業簡介
    • AbbVie Inc.
    • Alimera Sciences Inc.
    • Bausch & Lomb Incorporated（Bausch Health）
    • Enzo Biochem Inc.
    • Eyegate Pharmaceuticals Inc.
    • Eyepoint pharmaceuticals Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc
    • Santen Pharmaceutical Co. Ltd.
Product Code: SR112026A2759

The global uveitis treatment market size reached USD 1.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.8 Billion by 2034, exhibiting a growth rate (CAGR) of 4.31% during 2026-2034. The market is experiencing significant growth driven by the rising incidence of uveitis, ongoing research and development activities in various biologics and immunosuppressive treatments to diversify treatment possibilities, heightening emphasis on increasing awareness and early diagnosis, favorable government policies, and healthcare reimbursements.

Uveitis Treatment Market Trends:

Increasing Prevalence of Autoimmune Diseases

The uveitis treatment demand is stimulated by the increased rate of autoimmune diseases all over the world. As reported by the National Institutes of Health (NIH), autoimmune diseases are estimated to affect 23.5 million Americans, who have rheumatoid arthritis, inflammatory bowel disease, and lupus among other diseases develop uveitis as a sequel. It is important to note that this prevalence proves the high requirement for efficient uveitis therapies targeted at autoimmune diseases and stimulating the demand in the market. Thus, as these diseases move high across the world, treatment aims for uveitis and its therapies controlling the symptoms and it addresses the autoimmune processes that cause the disease to achieve better results in patients' lives.

Advancements in Biologics and Immunotherapy Therapies

Biologics and immunomodulatory therapies have revolutionized uveitis management by modulation of immune-mediated processes. The National Institutes of Health (NIH) has approved various biologics for autoimmune diseases, such as uveitis, signifying the change towards the use of cost-effective and effective biologics. Such therapies have benefits such as lower probability of side effects affecting other organs in the body than other treatments like corticosteroids which in turn is witnessing patients being more compliant to the treatment regimens that are recommended to them. As a result, there are continued markets in biotechnology and immunology leading to product development in biologics and immunomodulators extending the opportunities for the treatment of uveitis in the global market.

Rising Healthcare Expenditure and Research Funding

Increased government spending in healthcare systems, development strategies, and advances in healthcare are fueling the uveitis treatment market value. In the USA, the NIH supports significant funding to investigate uveitis and other auto-immune disorders, and this research has been a multisectoral and multiparty cooperation among universities, pharmaceutical industries, and hospitals. This financial support further brings a positive change to the progression of new treatments for uveitis as it pushes the development of new drugs, biologics, and treatment methods. Moreover, research grants and clinical trials that are supported by the government offer essential frameworks and resources to support the exploration of novel therapeutic profiles and verify the effectiveness of treatments. These dynamics make the uveitis treatment market highly research-intensive, as it capitalizes on the conversion of discoveries into clinically useful products and services that address existing requirements and enhance patient experience worldwide.

Uveitis Treatment Market Segmentation:

The publisher provides an analysis of the key trends in each segment of the market, along with forecasts at the global, regional, and country levels for 2026-2034. Our report has categorized the market based on treatment type, disease type, cause, and distribution channel.

Breakup by Treatment Type:

  • Corticosteroids
  • Immunosuppressant
  • Monoclonal Antibodies
  • Cycloplegic Agents
  • Antibiotics
  • Antivirals
  • Antifungal
  • Analgesics

Corticosteroids account for the majority of the market share

As per the uveitis treatment market forecast, Corticosteroids thus dominate the uveitis treatment market by share since they help reduce inflammation and maintain vision in affected individuals. The National Institutes of Health (NIH) reported that corticosteroids are the primary therapy for uveitis, as they yield fast control of inflammation and signs about different uveitis types, anterior, posterior, and panuveitis. The main indications for these medicines are to lessen the body's ability to fight infection in the eye and diminish inflammation, which provides fast and effective relief and enhances the degree of patient's health. Corticosteroids can be administered through eye drops, injections, and oral tablets depending on the intensity of the situation and condition of the patient. As corticosteroids present possible side-effects, including rising intraocular pressure and postoperative cataract formation by long-term application, they remain preferred to other competitors while moderately effective topical NSAIDs are not as popular in uveitis treatment despite frequent use in ophthalmological practice.

Breakup by Disease Type:

  • Anterior Uveitis
  • Posterior Uveitis
  • Intermediate Uveitis
  • Panuveitis

Anterior uveitis holds the largest share of the industry

Anterior uveitis holds a leading position in the segmentation of uveitis treatment because of its greater incidence and the necessity of unique therapy. The National Institutes of Health (NIH) categorizes anterior uveitis as the most prevalent type of uveitis which accounts for 50-60% of all uveitis reported in the United States. This is caused by inflammation of the structures of the anterior part of the eye known as the uvea, it is linked with autoimmune diseases, infections, or physical injury. As a result, the pattern implies the treatment of anterior uveitis requires different management strategies such as topical corticosteroids and pupil-dilating agents available, routinely managed in clinics or ophthalmology and retail outlets, thus creating a favorable

Breakup by Cause:

  • Infectious
  • Non-infectious

Non-infectious represents the leading market segment

Non-infectious drive the uveitis treatment market revenue as the condition is more frequent than the infection-related kind and was addressed using improving evidence-based individualized treatment targeting autoimmune and inflammation processes. According to the National Institutes of Health (NIH), non-infectious uveitis accounts for approximately 80-90% of all uveitis cases in the United States. This form of uveitis is more related to autoimmune diseases such as rheumatoid arthritis, inflammatory bowel disease, lupus, and the need for biologics and immunomodulatory agents. It has been observed by researchers from across the world that the cases of autoimmune diseases are continuously increasing, which strengthens the market position of the non-infectious forms of uveitis treatments. The modern pharmaceutical industry concentrates on the development of proper individual antiretirologic preparations to target more effectively the immunopathogenetic background of non-infectious uveitis with minimal side effects from systemic administration, thus creating a favorable uveitis treatment market outlook.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Retail pharmacies exhibit a clear dominance in the market

Retail pharmacies hold the largest market share of uveitis treatment primarily because they are easily accessible, and convenient, especially to the patients and they also engage in the dispensing of drugs. The National Community Pharmacists Association (NCPA) repoted that retail pharmacies in the United States dispense about 72% of prescriptions emphasizing the centrality of pharmacists in dispensing of medication. This uveitis treatment market overview shows that patients diagnosed with uveitis can conveniently get prescribed medicines such as corticosteroid, immunosuppressant, and biologic agents from the retail pharmacy at a faster pace. Additionally, retail pharmacies involve patient counseling, medication and health insurance information and management, which improves patient satisfaction and outcomes. Stakeholders use them to interface with the health systems and electronic health records, thereby providing continuity of care to patients with uveitis. Due to increased diversification of services and sophisticated patient and consumer focus in retail pharmacy, they significantly contribute to meeting the increasing needs of the market for uveitis medications and dominating the distribution of drugs.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest uveitis treatment market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Latin America (Brazil Mexico, and others) and the Middle East and Africa. According to the report, North America was the largest regional market for uveitis treatment.

As per the uveitis treatment market report, North America holds the largest market share due to its well-developed and advanced healthcare sector, acceptance of novel therapeutic management, and direct spending on research and development. As reported by the National Institutes of Health (NIH), a significant budget is devoted to autoimmune disease studies in the United States alone and there exists a conducive environment for numerous clinical trials and partnerships among various pharmaceutical entities, research institutions, and caregivers. Such strategic investment allows North American countries to take a frontline in the development and commercialization of biologics, immunomodulatory, and other approaches to treating uveitis. Also, presenting a higher frequency of autoimmune diseases which later develop into uveitis, the North American region needs efficient uveitis treatment and management, thereby carrying the market leadership of the global uveitis market.

Competitive Landscape:

  • The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the uveitis treatment industry include AbbVie Inc., Alimera Sciences Inc., Bausch & Lomb Incorporated (Bausch Health), Enzo Biochem Inc., Eyegate Pharmaceuticals Inc., Eyepoint Pharmaceuticals Inc., Novartis AG, Regeneron Pharmaceuticals Inc., and Santen Pharmaceutical Co. Ltd.
  • The uveitis treatment companies are focusing on the development of uveitis treatment include pharmaceutical companies and research institutions to meet the various challenges presented by the uveitis disease process through clinical trials. The market leaders such as AbbVie, Novartis, and Allergan are committed to research and development to launch new drugs that address specific immunological processes of uveitis development. For instance, the research strategies of AbbVie involve recent collaborations and clinical trials that explore the usage of biologics for autoimmune uveitis, proving the focus on precision medicine. Many of these activities are funded through government and research grants that promote academic-industry collaboration to advance therapeutic progress and improve patients' care in the context of the shifting uveitis treatment paradigm, thus fueling uveitis treatment industry growth.

Key Questions Answered in This Report

1. What was the size of the global uveitis treatment market in 2025?

2. What is the expected growth rate of the global uveitis treatment market during 2026-2034?

3. What has been the impact of COVID-19 on the global uveitis treatment market?

4. What are the key factors driving the global uveitis treatment market?

5. What is the breakup of the global uveitis treatment market based on the treatment type?

6. What is the breakup of the global uveitis treatment market based on the disease type?

7. What is the breakup of the global uveitis treatment market based on the cause?

8. What is the breakup of the global uveitis treatment market based on the distribution channel?

9. What are the key regions in the global uveitis treatment market?

10. Who are the key players/companies in the global uveitis treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Uveitis Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Corticosteroids
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Immunosuppressant
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Monoclonal Antibodies
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Cycloplegic Agents
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Antibiotics
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast
  • 6.6 Antivirals
    • 6.6.1 Market Trends
    • 6.6.2 Market Forecast
  • 6.7 Antifungal
    • 6.7.1 Market Trends
    • 6.7.2 Market Forecast
  • 6.8 Analgesics
    • 6.8.1 Market Trends
    • 6.8.2 Market Forecast

7 Market Breakup by Disease Type

  • 7.1 Anterior Uveitis
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Posterior Uveitis
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Intermediate Uveitis
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Panuveitis
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Cause

  • 8.1 Infectious
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Non-infectious
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Alimera Sciences Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
    • 15.3.3 Bausch & Lomb Incorporated (Bausch Health)
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 SWOT Analysis
    • 15.3.4 Enzo Biochem Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 Eyegate Pharmaceuticals Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6 Eyepoint pharmaceuticals Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7 Novartis AG
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Regeneron Pharmaceuticals Inc
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Santen Pharmaceutical Co. Ltd.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Uveitis Treatment Market: Sales Value (in Billion USD), 2020-2025
  • Figure 2: Global: Uveitis Treatment Market: Breakup by Treatment Type (in %), 2025
  • Figure 3: Global: Uveitis Treatment Market: Breakup by Disease Type (in %), 2025
  • Figure 4: Global: Uveitis Treatment Market: Breakup by Cause (in %), 2025
  • Figure 5: Global: Uveitis Treatment Market: Breakup by Distribution Channel (in %), 2025
  • Figure 6: Global: Uveitis Treatment Market: Breakup by Region (in %), 2025
  • Figure 7: Global: Uveitis Treatment Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 8: Global: Uveitis Treatment (Corticosteroids) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Uveitis Treatment (Corticosteroids) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Uveitis Treatment (Immunosuppressant) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Uveitis Treatment (Immunosuppressant) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Uveitis Treatment (Monoclonal Antibodies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Uveitis Treatment (Monoclonal Antibodies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Uveitis Treatment (Cycloplegic Agents) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Uveitis Treatment (Cycloplegic Agents) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Uveitis Treatment (Antibiotics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Uveitis Treatment (Antibiotics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Uveitis Treatment (Antivirals) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Uveitis Treatment (Antivirals) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Uveitis Treatment (Antifungal) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Uveitis Treatment (Antifungal) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Uveitis Treatment (Analgesics) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Uveitis Treatment (Analgesics) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Uveitis Treatment (Anterior Uveitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Uveitis Treatment (Anterior Uveitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Uveitis Treatment (Posterior Uveitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Uveitis Treatment (Posterior Uveitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: Global: Uveitis Treatment (Intermediate Uveitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: Global: Uveitis Treatment (Intermediate Uveitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: Global: Uveitis Treatment (Panuveitis) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: Global: Uveitis Treatment (Panuveitis) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Global: Uveitis Treatment (Infectious) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Global: Uveitis Treatment (Infectious) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Global: Uveitis Treatment (Non-infectious) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Global: Uveitis Treatment (Non-infectious) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: Global: Uveitis Treatment (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: Global: Uveitis Treatment (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Global: Uveitis Treatment (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Global: Uveitis Treatment (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: Global: Uveitis Treatment (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: Global: Uveitis Treatment (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: Global: Uveitis Treatment (Other Distribution Channels) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: Global: Uveitis Treatment (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: North America: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: North America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: United States: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: United States: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Canada: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Canada: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Asia Pacific: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Asia Pacific: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: China: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: China: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: Japan: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: Japan: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: India: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: India: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: South Korea: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: South Korea: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Australia: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Australia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Indonesia: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Indonesia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Europe: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Europe: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Germany: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Germany: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: France: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: France: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: United Kingdom: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: United Kingdom: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Italy: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Italy: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 76: Spain: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 77: Spain: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 78: Russia: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 79: Russia: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 80: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 81: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 82: Latin America: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 83: Latin America: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 84: Brazil: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 85: Brazil: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 86: Mexico: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 87: Mexico: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 88: Others: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 89: Others: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 90: Middle East and Africa: Uveitis Treatment Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 91: Middle East and Africa: Uveitis Treatment Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 92: Global: Uveitis Treatment Industry: SWOT Analysis
  • Figure 93: Global: Uveitis Treatment Industry: Value Chain Analysis
  • Figure 94: Global: Uveitis Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Uveitis Treatment Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Uveitis Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2026-2034
  • Table 3: Global: Uveitis Treatment Market Forecast: Breakup by Disease Type (in Million USD), 2026-2034
  • Table 4: Global: Uveitis Treatment Market Forecast: Breakup by Cause (in Million USD), 2026-2034
  • Table 5: Global: Uveitis Treatment Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Uveitis Treatment Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Uveitis Treatment Market Structure
  • Table 8: Global: Uveitis Treatment Market: Key Players